Exchange Traded Concepts LLC Has $171,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Exchange Traded Concepts LLC cut its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 19.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,286 shares of the company’s stock after selling 3,031 shares during the period. Exchange Traded Concepts LLC’s holdings in Day One Biopharmaceuticals were worth $171,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of DAWN. Wellington Management Group LLP lifted its position in Day One Biopharmaceuticals by 77.7% during the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock worth $3,051,000 after purchasing an additional 91,393 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in Day One Biopharmaceuticals by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after purchasing an additional 1,445 shares during the period. ProShare Advisors LLC increased its position in Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after purchasing an additional 1,447 shares during the period. Summit Rock Advisors LP acquired a new stake in Day One Biopharmaceuticals during the 1st quarter valued at approximately $851,000. Finally, Altitude Crest Partners Inc. acquired a new stake in Day One Biopharmaceuticals during the 1st quarter valued at approximately $3,230,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on DAWN shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. JPMorgan Chase & Co. reduced their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC raised their price objective on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $35.71.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 10,681 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $149,534.00. Following the transaction, the chief executive officer now directly owns 98,932 shares in the company, valued at approximately $1,385,048. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Charles N. York II sold 2,633 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the sale, the chief financial officer now directly owns 232,485 shares in the company, valued at $3,254,790. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeremy Bender sold 10,681 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $149,534.00. Following the sale, the chief executive officer now owns 98,932 shares in the company, valued at $1,385,048. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,748 shares of company stock worth $689,072. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Stock Down 0.5 %

Shares of DAWN opened at $14.93 on Tuesday. Day One Biopharmaceuticals, Inc. has a 12-month low of $9.76 and a 12-month high of $18.07. The business’s fifty day moving average is $14.08 and its 200 day moving average is $14.37. The stock has a market cap of $1.30 billion, a P/E ratio of -5.95 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.70. The company had revenue of $8.19 million for the quarter, compared to the consensus estimate of $0.90 million. On average, analysts expect that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current year.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.